Novo Nordisk CEO Mike Doustdar told CNBC on Tuesday that the pharmaceutical giant is considering M&A opportunities to strengthen its drug pipeline, as it faces growing competition in the weight-loss market. Doustdar stated the company is interested in filling gaps by acquiring firms that have produced or are about to introduce better drugs than Novo Nordisk can develop on its own.